Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575592 | 0.98 | ATM (0.41) | ALDH1A1ATMHPGDMMP1MMP2 | |
| SCHEMBL37699 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL329111 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL10660748 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL10658257 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL25231611 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL2554891 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL2558338 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL20664588 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL10661213 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | TOBIRA THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | ALDH1A1 2749/4885ATM 4339/4885HPGD 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.